Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive diso… Read more
Neumora Therapeutics, Inc. (NMRA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.353x
Based on the latest financial reports, Neumora Therapeutics, Inc. (NMRA) has a cash flow conversion efficiency ratio of -0.353x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-46.63 Million) by net assets ($132.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Neumora Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Neumora Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Neumora Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neumora Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing AriTime Intelligent Control Co Ltd
SHG:600560
|
0.019x |
|
FibraHotel
MX:FIHO12
|
0.027x |
|
Guangzhou Jiacheng
SHG:603535
|
0.031x |
|
5N Plus Inc
PINK:FPLSF
|
0.092x |
|
Grupo Catalana Occidente
MC:GCO
|
0.098x |
|
Suzhou GYZ Electronic Technology Co. Ltd. A
SHG:688260
|
0.057x |
|
Tianjin Capital Environmental Protection Group Company Limited
PINK:TNJIF
|
0.001x |
|
GMM Pfaudler Limited
NSE:GMMPFAUDLR
|
0.054x |
Annual Cash Flow Conversion Efficiency for Neumora Therapeutics, Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Neumora Therapeutics, Inc. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $287.06 Million | $-182.94 Million | -0.637x | -83.08% |
| 2023-12-31 | $469.08 Million | $-163.28 Million | -0.348x | -235.38% |
| 2022-12-31 | $-446.85 Million | $-114.90 Million | 0.257x | +10.88% |
| 2021-12-31 | $-325.22 Million | $-75.42 Million | 0.232x | -18.21% |
| 2020-12-31 | $-94.38 Million | $-26.76 Million | 0.284x | -99.98% |
| 2019-12-31 | $-21.00K | $-26.76 Million | 1274.286x | -- |